Chardan Capital analyst Keay Nakae maintained Dyne Therapeutics with a Buy and lowered the price target from $50 to $38.

Dyne also reported new positive long-term data from adult DM1 patients enrolled in the randomized, placebo-controlled multiple ascending dose (MAD) portion of the DYNE-101 ACHIEVE trial, including ...

Dyne Therapeutics completes $230 million public offering of 27.8 million shares to advance neuromuscular disease therapies.

Aura Minerals (Nasdaq: AUGO), a company focused on the development and operation of gold and base metal projects in the Americas, visits the Nasdaq MarketSite in Times Square.In honor of the ...

Ollie's rings Nasdaq opening bell in Times SquareMore for You Police union threatens legal action over Trump visit John Oliver Reacts To ‘The Late Show With Stephen Colbert' Cancelation ...

The company had the honor of ringing the bell to mark the company’s 10th anniversary of its listing on the exchange, the opening of its 600th store, and its expansion into its 34th state.

The market failed to keep its gains as stocks lost steam in the final hour of trading. The S&P 500 was down 0.1% on Tuesday afternoon after barely managing to breathe above the breakeven line ...

HARRISBURG, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) (the “Company”) today rang the Nasdaq Stock Market opening bell to celebrate the 10 th ...

Stocks extended their advance on Thursday as the early closing bell approached, bolstered by strong economic data that has cast doubt on the likelihood of an interest-rate cut from the Federal ...

HARRISBURG, Pa. (WHTM)– Ollie’s Bargain Outlet Holdings, Inc. rang the Nasdaq Stock Market opening bell Tuesday morning to celebrate the company’s 10th anniversary of its listing … ...